allopurinol 200 mg

DRUG2 trials

Sponsors

Ardea Biosciences, Inc., Poznan University of Medical Sciences

Conditions

Cardiovascular DiseasesHealthyUric Acid

Phase 1

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

CompletedNCT02581553

Ardea Biosciences, Inc.Healthy

Start: 2015-10-31End: 2016-08-31Updated: 2016-12-19

Phase 3

The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

RecruitingNCT05943821

Poznan University of Medical SciencesCardiovascular Diseases, Uric Acid

Start: 2023-09-01End: 2028-07-31Target: 1116Updated: 2025-01-06

Related Papers

Randomised, double-blind, placebo-controlled study evaluating the effect of allopurinol on the risk of cardiovascular events in patients with high and very high cardiovascular risk, including the presence of long-COVID-19 syndrome: the ALL-VASCOR study protocol

BMJ Open2024-07-011 citations